The most significant adverse effect of α-particle PSMA-targeted radionuclide therapy with small molecules (i.e., PSMA-617, PSMA-I&T) is xerostomia, making the salivary glands a key dose-limiting organ (28). The gene discussed is FOLH1; the disease is xerostomia.